ONC
BeOne Medicines Ltd. NASDAQ Listed Feb 2, 2016$270.15
+2.84%
vs $262.68
Mkt Cap $30.6B
52w Low $240.99
21.4% of range
52w High $377.47
50d MA $295.53
200d MA $318.35
P/E (TTM)
8.2x
EV/EBITDA
45.3x
P/B
6.8x
Debt/Equity
0.5x
ROE
6.6%
P/FCF
32.5x
RSI (14)
35.30
ATR (14)
$7.22
Beta
0.54
50d MA
$295.53
200d MA
$318.35
Avg Volume
283.2K
BeOne Medicines, formerly known as BeiGene, is a global oncology company focused on discovering, developing, and commercializing innovative cancer therapies. Founded in 2010 and headquartered in Cambridge, Massachusetts—with operations spanning over 45 countries across six continents—the company rebranded as BeOne in late 2024 and redomiciled to Basel, Switzerland in 2025. BeOne has established itself as a leader in immuno-oncology and targeted therapies, with key assets including Tevimbra (tislelizumab), a PD-1 monoclonal antibody approved for multiple cancer indications globally, and Brukinsa (zanubrutinib), a Bruton's tyrosine kinase (BTK) inhibitor that surpassed $1.3 billion in annual sales and is approved in major markets such as the U.S., Europe, and China. The company’s strategy combines internal R&D with the development of assets sourced from external partnerships, driving a robust pipeline across hematologic malignancies and solid tumors.
C/O BEONE MEDICINES I GMBH · BASEL 4051 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 6, 2026 | TNS | 0.81 | 26.65 | +3206.5% | 313.32 | +0.2% | +1.2% | -1.5% | -0.4% | +1.4% | +0.5% | — |
| Feb 26, 2026 | TNS | 1.60 | 0.58 | -63.8% | 322.37 | -1.2% | -1.7% | -0.8% | -5.5% | +0.7% | -2.0% | — |
| Nov 6, 2025 | TNS | 0.72 | 1.09 | +51.4% | 332.36 | -5.1% | -3.7% | +2.9% | +4.4% | +9.8% | -2.4% | — |
| Aug 6, 2025 | TNS | 0.48 | 0.84 | +75.0% | 298.52 | -0.4% | -0.1% | -3.4% | +0.5% | -0.6% | +6.7% | — |
| May 7, 2025 | TNS | -0.71 | 1.22 | +271.8% | 232.25 | +1.7% | +1.6% | -1.7% | +0.5% | -3.7% | -2.1% | — |
| Feb 27, 2025 | TNS | -0.88 | -1.43 | -62.5% | 278.38 | -2.9% | -2.4% | -9.7% | +4.8% | +1.9% | -2.0% | — |
| Nov 12, 2024 | TNS | -0.88 | -1.15 | -30.7% | 193.64 | +2.0% | +0.9% | -1.1% | -2.1% | -0.8% | +0.0% | — |
| Aug 7, 2024 | TNS | -2.10 | -1.15 | +45.2% | 176.73 | +1.2% | +3.6% | -0.1% | +4.0% | -1.5% | -0.3% | — |
| Mar 31, 2024 | TNS | — | -2.41 | — | 156.39 | — | — | +1.8% | -3.8% | -0.8% | -1.6% | — |
| Dec 31, 2023 | TNS | — | -25.53 | — | 180.36 | — | — | -1.9% | +2.5% | -3.2% | -5.9% | — |
| Sep 30, 2023 | TNS | — | 2.01 | — | 179.87 | — | — | -0.8% | -2.4% | -2.9% | +0.9% | — |
| Jun 30, 2023 | TNS | — | -3.64 | — | 178.30 | +0.3% | +1.4% | +5.9% | -1.1% | +0.1% | +1.6% | — |
| Mar 31, 2023 | BMO | — | -3.34 | — | 215.53 | +0.0% | -1.2% | +1.0% | -1.4% | +12.5% | -1.4% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 16 | Jefferies | Downgrade | Buy → Hold | — | $284.05 | $286.11 | +0.7% | +2.0% | -0.8% | -1.8% | +0.2% | -2.6% |
| Feb 27 | Barclays | Maintains | Overweight → Overweight | — | $322.37 | $318.66 | -1.2% | -1.7% | -0.8% | -5.5% | +0.7% | -2.0% |
| Feb 27 | Truist | Maintains | Buy → Buy | — | $322.37 | $318.66 | -1.2% | -1.7% | -0.8% | -5.5% | +0.7% | -2.0% |
| Feb 27 | RBC Capital | Maintains | Outperform → Outperform | — | $322.37 | $318.66 | -1.2% | -1.7% | -0.8% | -5.5% | +0.7% | -2.0% |
| Feb 27 | Guggenheim | Maintains | Buy → Buy | — | $322.37 | $318.66 | -1.2% | -1.7% | -0.8% | -5.5% | +0.7% | -2.0% |
| Feb 4 | Barclays | Maintains | Overweight → Overweight | — | $346.38 | $348.79 | +0.7% | +1.6% | -1.4% | +2.0% | -1.4% | +1.3% |
| Nov 18 | RBC Capital | Maintains | Outperform → Outperform | — | $376.63 | $362.46 | -3.8% | -3.4% | -2.8% | -1.3% | -0.4% | -4.3% |
| Nov 10 | Citigroup | Maintains | Buy → Buy | — | $319.97 | $329.00 | +2.8% | +2.9% | +4.4% | +9.8% | -2.4% | -0.7% |
| Nov 7 | RBC Capital | Maintains | Outperform → Outperform | — | $332.36 | $315.53 | -5.1% | -3.7% | +2.9% | +4.4% | +9.8% | -2.4% |
| Nov 7 | Citizens | Maintains | Market Outperform → Market Outperform | — | $332.36 | $315.53 | -5.1% | -3.7% | +2.9% | +4.4% | +9.8% | -2.4% |
| Oct 20 | Morgan Stanley | Maintains | Overweight → Overweight | — | $316.42 | $318.00 | +0.5% | +0.7% | -0.9% | -0.7% | -1.1% | +0.3% |
| Oct 8 | JP Morgan | Maintains | Overweight → Overweight | — | $341.62 | $347.82 | +1.8% | +2.8% | -4.4% | -4.7% | +2.2% | -1.9% |
| Aug 7 | RBC Capital | Maintains | Outperform → Outperform | — | $298.52 | $297.21 | -0.4% | -0.1% | -3.4% | +0.5% | -0.6% | +6.7% |
| Aug 7 | Guggenheim | Maintains | Buy → Buy | — | $298.52 | $297.21 | -0.4% | -0.1% | -3.4% | +0.5% | -0.6% | +6.7% |
| Jul 17 | JP Morgan | Maintains | Overweight → Overweight | — | $279.16 | $297.00 | +6.4% | +4.0% | +1.4% | -0.9% | +1.3% | -0.3% |
| Jul 16 | RBC Capital | Maintains | Outperform → Outperform | — | $269.70 | $272.99 | +1.2% | +3.5% | +4.0% | +1.4% | -0.9% | +1.3% |
| Jun 27 | JP Morgan | Maintains | Overweight → Overweight | — | $254.49 | $245.51 | -3.5% | -5.2% | +0.4% | +1.3% | -0.3% | +0.5% |
| Jun 27 | Morgan Stanley | Maintains | Overweight → Overweight | — | $254.49 | $245.51 | -3.5% | -5.2% | +0.4% | +1.3% | -0.3% | +0.5% |
| Jun 27 | RBC Capital | Maintains | Outperform → Outperform | — | $254.49 | $245.51 | -3.5% | -5.2% | +0.4% | +1.3% | -0.3% | +0.5% |
| May 8 | Guggenheim | Maintains | Buy → Buy | — | $232.25 | $236.28 | +1.7% | +1.6% | -1.7% | +0.5% | -3.7% | -2.1% |
| May 8 | RBC Capital | Maintains | Outperform → Outperform | — | $232.25 | $236.28 | +1.7% | +1.6% | -1.7% | +0.5% | -3.7% | -2.1% |
| Apr 28 | RBC Capital | Maintains | Outperform → Outperform | — | $244.90 | $247.67 | +1.1% | +1.9% | +0.1% | +4.0% | -1.6% | +0.1% |
| Apr 24 | TD Securities | Maintains | Buy → Buy | — | $249.13 | $257.88 | +3.5% | +2.8% | -4.4% | +1.9% | +0.1% | +4.0% |
| Apr 21 | JP Morgan | Maintains | Overweight → Overweight | — | $230.98 | $231.28 | +0.1% | -0.8% | +10.3% | -1.4% | +2.8% | -4.4% |
| Apr 16 | Guggenheim | Maintains | Buy → Buy | — | $238.84 | $235.00 | -1.6% | -4.5% | +1.2% | -0.8% | +10.3% | -1.4% |
| Apr 10 | Guggenheim | Maintains | Buy → Buy | — | $206.32 | $218.64 | +6.0% | +1.0% | +10.6% | +5.4% | -1.6% | -4.5% |
| Feb 28 | Macquarie | Maintains | Outperform → Outperform | — | $278.38 | $270.24 | -2.9% | -2.4% | -9.7% | +4.8% | +1.9% | -2.0% |
| Feb 28 | Citizens Capital Markets | Maintains | Market Outperform → Market Outperform | — | $278.38 | $270.24 | -2.9% | -2.4% | -9.7% | +4.8% | +1.9% | -2.0% |
| Nov 13 | TD Cowen | Maintains | Buy → Buy | — | $193.64 | $197.44 | +2.0% | +0.9% | -1.1% | -2.1% | -0.8% | +0.0% |
| Oct 22 | JP Morgan | Maintains | Overweight → Overweight | — | $219.92 | $219.14 | -0.4% | +0.3% | +0.2% | -3.1% | -0.6% | +2.1% |
| Aug 20 | JP Morgan | Maintains | Overweight → Overweight | — | $192.50 | $194.19 | +0.9% | +0.9% | +1.9% | -1.2% | -0.9% | +2.8% |
| Aug 8 | Citigroup | Maintains | Buy → Buy | — | $176.73 | $178.80 | +1.2% | +3.6% | -0.1% | +4.0% | -1.5% | -0.3% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Jun 16, 2026 | OYLER JOHNDir/Off | Chief Executive Officer | Sell | 333 | $266.69 | $89K | — | — | — |
| Jun 16, 2026 | OYLER JOHNDir/Off | Chief Executive Officer | Sell | 1,710 | $265.99 | $455K | 333 | — | — |
| Jun 16, 2026 | OYLER JOHNDir/Off | Chief Executive Officer | Sell | 1,650 | $264.87 | $437K | 2,043 | — | — |
| Jun 16, 2026 | Wu XiaobinOff | President and COO | Sell | 1,357 | $266.76 | $362K | — | — | — |
| Jun 16, 2026 | Wang LaiOff | President, Global Head of R&D | Sell | 1,169 | $265.39 | $310K | — | — | — |
| Jun 16, 2026 | Lee Chan HenryOff | SVP, General Counsel | Sell | 590 | $265.98 | $157K | — | — | — |
| Jun 11, 2026 | OYLER JOHNDir/Off | Chief Executive Officer | Sell | 149 | $258.81 | $39K | — | -1.60% | — |
| Jun 11, 2026 | OYLER JOHNDir/Off | Chief Executive Officer | Sell | 200 | $258.28 | $52K | 149 | -1.60% | — |
| Jun 11, 2026 | OYLER JOHNDir/Off | Chief Executive Officer | Sell | 859 | $257.59 | $221K | 349 | -1.60% | — |
| Jun 11, 2026 | OYLER JOHNDir/Off | Chief Executive Officer | Sell | 741 | $256.23 | $190K | 1,208 | -1.60% | — |
| Jun 11, 2026 | Ball Titus B.Off | Principal Accounting Officer | Sell | 120 | $257.53 | $31K | — | -1.60% | — |
| Jun 11, 2026 | Ball Titus B.Off | Principal Accounting Officer | Sell | 49 | $256.39 | $13K | 120 | -1.60% | — |
| Jun 11, 2026 | Wu XiaobinOff | President and COO | Sell | 626 | $261.20 | $164K | — | -1.60% | — |
| Jun 11, 2026 | Wang LaiOff | President, Global Head of R&D | Sell | 756 | $261.00 | $197K | — | -1.60% | — |
| Jun 11, 2026 | Lee Chan HenryOff | SVP, General Counsel | Sell | 428 | $257.63 | $110K | — | -1.60% | — |
| Jun 11, 2026 | Rosenberg AaronOff | Chief Financial Officer | Sell | 631 | $257.74 | $163K | — | -1.60% | — |
| Jun 8, 2026 | OYLER JOHNDir/Off | Chief Executive Officer | Sell | 1,120 | $271.14 | $304K | — | -1.27% | -0.47% |
| Jun 8, 2026 | OYLER JOHNDir/Off | Chief Executive Officer | Sell | 3,820 | $270.38 | $1.0M | 1,120 | -1.27% | -0.47% |
| Jun 8, 2026 | Ball Titus B.Off | Principal Accounting Officer | Sell | 36 | $272.08 | $10K | — | -1.27% | -0.47% |
| Jun 8, 2026 | Ball Titus B.Off | Principal Accounting Officer | Sell | 100 | $271.06 | $27K | 36 | -1.27% | -0.47% |
| Jun 8, 2026 | Wu XiaobinOff | President and COO | Sell | 40 | $270.55 | $11K | — | -1.27% | -0.47% |
| Jun 8, 2026 | Wu XiaobinOff | President and COO | Sell | 1,444 | $269.33 | $389K | 40 | -1.27% | -0.47% |
| Jun 8, 2026 | Wang LaiOff | President, Global Head of R&D | Sell | 40 | $270.73 | $11K | — | -1.27% | -0.47% |
| Jun 8, 2026 | Wang LaiOff | President, Global Head of R&D | Sell | 1,327 | $269.34 | $357K | 40 | -1.27% | -0.47% |
| Jun 8, 2026 | Lee Chan HenryOff | SVP, General Counsel | Sell | 160 | $271.26 | $43K | — | -1.27% | -0.47% |
| Jun 8, 2026 | Lee Chan HenryOff | SVP, General Counsel | Sell | 711 | $270.24 | $192K | 160 | -1.27% | -0.47% |
| Jun 1, 2026 | Yi QingqingDir | — | Sell | 235 | $279.13 | $66K | — | +0.33% | -1.70% |
| May 22, 2026 | BAKER BROS. ADVISORS LP | — | Sell | 2,756 | $23.79 | $66K | 142,566 | -3.14% | +1.57% |
| May 22, 2026 | BAKER BROS. ADVISORS LP | — | Sell | 2,743 | $23.85 | $65K | 145,322 | -3.14% | +1.57% |
| May 22, 2026 | Dugan MargaretDir | — | Sell | 212 | $309.60 | $66K | — | -3.14% | +1.57% |
8-K · 5.02
!!! Very High
BeOne Medicines Ltd. -- 8-K 5.02: Executive Change
Jun 11
8-K · 2.02
!! High
BeOne Medicines Ltd. -- 8-K 2.02: Earnings Results
BeOne Medicines reported Q1 2026 financial results, providing investors with updated operational performance and financial health metrics for the quarter ended March 31, 2026.
May 6
Institutional (13F) — Top 0
All ↗
No 13F holders found.
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$30.65B
Enterprise Value
$27.91B
P/E (TTM)
8.21x
Forward P/E
44.24x
PEG Ratio
-0.18x
P/B
6.76x
P/S
5.74x
P/FCF
32.54x
EV/EBITDA
45.26x
Shares Out
113.4M
Financials (TTM)
Revenue
$5.34B
Net Income
$286.9M
EBITDA
$616.8M
Free Cash Flow
$941.7M
Op Cash Flow
$1.13B
EPS Basic
$34.19
EPS Diluted
$32.89
EPS Forward
$6.11
Gross Margin
87.5%
Op Margin
8.4%
Net Margin
5.4%
Balance Sheet
Total Assets
$8.19B
Total Liab.
$3.83B
Total Equity
$4.36B
Cash
$4.55B
LT Debt
$1.81B
Book Value/Sh
$39.99
Debt/Equity
0.46x
Current Ratio
3.41
Quick Ratio
3.08
Returns & Growth
ROE
6.6%
ROA
3.5%
ROIC
4.7%
Rev Growth YoY
+40.2%
EPS Growth YoY
+658.7%
Price Returns
2W
-5.5%
1M
-2.5%
3M
-9.2%
6M
-15.5%
12M
+17.2%
Technicals
52W High
$377.47
52W Low
$240.99
50d MA
$295.53
200d MA
$318.35
RSI (14)
35.30
ATR (14)
$7.22
Beta
0.54
Avg Volume
283K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$401.29
High
$425.00
Low
$340.00
Median
$411.00
Data updated apr 26, 2026 5:27pm
· Source: financialmodelingprep.com